2025
Endovascular management of tandem occlusions: current evidence and future directions
Krothapalli N, Heit J, de Havenon A, Singhal A, Sussman E, Hasan D, Mac Grory B. Endovascular management of tandem occlusions: current evidence and future directions. Journal Of NeuroInterventional Surgery 2025, jnis-2025-023793. PMID: 40780815, PMCID: PMC12338063, DOI: 10.1136/jnis-2025-023793.Peer-Reviewed Original ResearchRandomized Controlled TrialsEndovascular thrombectomyEndovascular managementAssociated with high mortalityArtery steno-occlusionOptimal antithrombotic therapyStandard treatment approachExtracranial carotid lesionsIntracranial revascularizationAntithrombotic therapyClot burdenTandem occlusionSteno-occlusionClinical predicamentCarotid lesionsIntravenous thrombolysisOptimal managementOcclusion strokeObservational studyPractice patternsControlled TrialsTreatment approachesHigher mortalityAnterograde flowNarrative reviewAntithrombotic Therapy in Patients With Isolated Peripheral Arterial Disease Undergoing Peripheral Vascular Interventions
Said S, Alameddine D, Fischer U, Zwibelman H, Kabbani L, Kashyap V, Tonnessen B, Cardella J, Guzman R, Chaar C. Antithrombotic Therapy in Patients With Isolated Peripheral Arterial Disease Undergoing Peripheral Vascular Interventions. Journal Of Vascular Surgery 2025, 81: e56-e58. DOI: 10.1016/j.jvs.2025.03.124.Peer-Reviewed Original ResearchThe Incidence and Significance of Delayed Bleeding Events After Lower Extremity Revascularization in Patients with Advanced Peripheral Arterial Disease
Hundito A, Wells N, Tuttle M, Alameddine D, Huttler J, Slade M, Strosberg D, Lee A, Guzman R, Ochoa Chaar C. The Incidence and Significance of Delayed Bleeding Events After Lower Extremity Revascularization in Patients with Advanced Peripheral Arterial Disease. Journal Of Vascular Surgery 2025 PMID: 40187383, DOI: 10.1016/j.jvs.2025.03.394.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseBleeding eventsBleeding episodesAdvanced peripheral arterial diseaseArtery diseaseAntithrombotic therapyExtremity revascularizationRetrospective review of patientsIncidence of bleeding eventsAssociated with worse overall outcomesDelayed bleeding eventsDiscontinuation of ASAPrescription of antithrombotic therapyRecurrent bleeding episodesReview of patientsChronic renal insufficiencyEnd-stage renal diseaseOutcomes of patientsTertiary care centerHistory of smokingRecurrent bleeding eventsLong-term outcomesCoronary artery diseaseLower-extremity revascularizationANTITHROMBOTIC THERAPY AND OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Siami S, Maleki S, Kazemian S, ebrahimi E, Ebrahimzade M, Jodeiri F, Hajiqasemi M, Ebrahimi S, Mehdizadeh M, Aghaei M, Bastan M, Sabet M, Nazari R, Ebrahimi P, Rana J, Nanna M, Giri J, Kolte D, Alkhouli M, Hosseini K. ANTITHROMBOTIC THERAPY AND OUTCOMES AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT: AN UPDATED SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS. Journal Of The American College Of Cardiology 2025, 85: 888. DOI: 10.1016/s0735-1097(25)01372-5.Peer-Reviewed Original ResearchVariations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy After Lower Extremity Revascularization for Peripheral Artery Disease
Wells N, Alameddine D, Dhanda U, Tran L, Silva D, Slade M, Guzman R, Ochoa Chaar C. Variations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy After Lower Extremity Revascularization for Peripheral Artery Disease. Journal Of Vascular Surgery 2025 PMID: 40122313, DOI: 10.1016/j.jvs.2025.03.183.Peer-Reviewed Original ResearchLower extremity revascularizationPeripheral arterial diseaseDuration of clopidogrel therapyClopidogrel therapyAntithrombotic prescriptionAntithrombotic combinationsAntithrombotic therapyExtremity revascularizationArtery diseasePatients treated with clopidogrelAssociated with improved survivalClinical characteristics of patientsMedical records of patientsLong-term follow-upChronic renal insufficiencyMACE-free survivalAssociated with bleedingElectronic medical records of patientsAdverse cardiac eventsKaplan-Meier curvesRecords of patientsTertiary care centerCongestive heart failureLong-term outcomesComparison of patientsAntithrombotic Therapy In Patients With Atrial Fibrillation Undergoing Peripheral Vascular Interventions
Said S, Alameddine D, Aboian E, Strosberg D, Tonnessen B, Cardella J, Guzman R, Chaar C. Antithrombotic Therapy In Patients With Atrial Fibrillation Undergoing Peripheral Vascular Interventions. Annals Of Vascular Surgery 2025, 112: 436-437. DOI: 10.1016/j.avsg.2024.11.070.Peer-Reviewed Original Research
2024
Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS
Fanaroff A, Vora A, Wojdyla D, Mehran R, Granger C, Goodman S, Aronson R, Windecker S, Alexander J, Lopes R. Effect of apixaban versus vitamin K antagonist and aspirin versus placebo on days alive and out of hospital: An analysis from AUGUSTUS. American Heart Journal 2024, 280: 60-69. PMID: 39557109, DOI: 10.1016/j.ahj.2024.11.005.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeTime-to-event analysisAtrial fibrillationCoronary syndromeClinical trialsEffect of antithrombotic therapyVitamin K antagonistsProportion of patientsRobust variance estimationRandomized clinical trialsClinical trial endpointsPercutaneous coronary interventionK antagonistsAntithrombotic therapyPoisson regressionTreatment armsFollow-upIschemic eventsPlaceboRate ratiosAntithrombotic agentsTrial endpointsWarfarinCoronary interventionIntervention methodsAntithrombotic Strategies for Patients With Peripheral Artery Disease JACC Scientific Statement
Bonaca M, Barnes G, Bauersachs R, Bessada Y, Conte M, Dua A, Hess C, Serhal M, Mena-Hurtado C, Weitz J, Beckman J. Antithrombotic Strategies for Patients With Peripheral Artery Disease JACC Scientific Statement. Journal Of The American College Of Cardiology 2024, 84: 936-952. PMID: 39197984, DOI: 10.1016/j.jacc.2024.06.027.Peer-Reviewed Original ResearchConceptsPeripheral arterial diseaseAntithrombotic strategiesArtery diseaseResponse to antithrombotic therapyLimb eventsRisk of bleedingCoronary artery diseaseAdverse limb eventsAntithrombotic therapyMultidisciplinary working groupClinical scenariosPatientsAssessment of benefit-riskBenefit-riskAnticoagulationDiseaseScientific statementPatient-centeredBleedingRestarting Antithrombotic Therapies After Endoscopic Sinus Surgery: A Systematic Review
Boyi T, Richmond R, Kayastha D, Manes R, Rimmer R. Restarting Antithrombotic Therapies After Endoscopic Sinus Surgery: A Systematic Review. Annals Of Otology Rhinology & Laryngology 2024, 133: 633-638. PMID: 38557289, DOI: 10.1177/00034894241245840.Peer-Reviewed Original ResearchEndoscopic sinus surgeryAntithrombotic therapySinus surgerySystematic reviewResumption of antithrombotic therapyRisk of perioperative hemorrhageFull-text reviewPreferred Reporting ItemsCase-control studyWeb of ScienceCINAHL databasesReporting ItemsIndependent reviewersUnique articlesPerioperative hemorrhageTherapy resumptionCohort studyAntiplatelet therapyInclusion criteriaPatient morbidityAntiplatelet agentsPrimary outcomeTherapySurgeryAntiplateletOptimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease
Talasaz A, Sadeghipour P, Ortega-Paz L, Kakavand H, Aghakouchakzadeh M, Beavers C, Fanikos J, Eikelboom J, Siegal D, Monreal M, Jimenez D, Vaduganathan M, Castellucci L, Cuker A, Barnes G, Connors J, Secemsky E, Van Tassell B, De Caterina R, Kurlander J, Aminian A, Piazza G, Goldhaber S, Moores L, Middeldorp S, Kirtane A, Elkind M, Angiolillo D, Konstantinides S, Lip G, Stone G, Cushman M, Krumholz H, Mehran R, Bhatt D, Bikdeli B. Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nature Reviews Cardiology 2024, 21: 574-592. PMID: 38509244, DOI: 10.1038/s41569-024-01003-3.Peer-Reviewed Original ResearchRisk of gastrointestinal bleedingGastrointestinal bleedingAntithrombotic therapyHigh risk of gastrointestinal bleedingIncreased risk of bleedingRisk of bleedingGastrointestinal diseasesEfficacy of antithrombotic agentsAntithrombotic regimensConcomitant medicationsRisk stratificationClinical evidenceGastrointestinal comorbiditiesMultidisciplinary discussionAntithrombotic drugsAntithrombotic agentsIncreased riskHigh riskPatientsGastrointestinal disordersCardiovascular diseaseTherapyBleedingDiseaseMedical societies
2023
Assessing the safety of continued perioperative antithrombotic therapy in endoscopic airway surgery for laryngotracheal stenosis
Shah H, Reeder A, Rohrbaugh T, Kohli N. Assessing the safety of continued perioperative antithrombotic therapy in endoscopic airway surgery for laryngotracheal stenosis. American Journal Of Otolaryngology 2023, 44: 103857. PMID: 37030129, PMCID: PMC10033492, DOI: 10.1016/j.amjoto.2023.103857.Peer-Reviewed Original ResearchConceptsEndoscopic airway surgeryAntithrombotic therapyAirway surgeryPerioperative continuationLaryngotracheal stenosisEndoscopic surgeryOpen airway surgeryPerioperative antithrombotic therapyCases of patientsPerioperative cessationPreoperative continuationPostoperative bleedingProlonged intubationAntithrombotic usePrimary outcomeRetrospective studyTracheal stenosisSingle institutionProspective InvestigationInclusion criteriaSurgeryPatientsTherapyComplicationsStenosis
2022
Thrombosis questions from the inpatient wards
Goshua G, Bendapudi P, Lee A. Thrombosis questions from the inpatient wards. Hematology 2022, 2022: 481-490. PMID: 36485139, PMCID: PMC9819989, DOI: 10.1182/hematology.2022000384.Peer-Reviewed Original ResearchConceptsCancer-associated thrombosisInpatient wardsPurpura fulminansIntermediate-dose anticoagulationEtiology of thrombocytopeniaMajor clinical trialsCases of thrombosisCoronavirus disease 2019Recent prospective dataCOVID-19Antithrombin replacementAnticoagulation therapyAntiplatelet therapyAntithrombotic therapyAnticoagulation managementMicrovascular thrombosisPlasma transfusionHospitalized patientsAntiplatelet agentsThromboembolic diseasePlatelet countConsensus guidelinesProspective dataClinical trialsDisease 2019Variability in Antithrombotic Therapy after Infrainguinal Lower Extremity Bypass
Brahmandam A, Lee M, Bellamkonda K, Provance JB, Sumpio B, Ochoa Chaar CI, Smolderen KG, Mena-Hurtado C, Guzman RJ. Variability in Antithrombotic Therapy after Infrainguinal Lower Extremity Bypass. Annals Of Vascular Surgery 2022, 88: 51-62. PMID: 36245106, DOI: 10.1016/j.avsg.2022.08.016.Peer-Reviewed Original ResearchConceptsInfrainguinal lower extremity bypassLower extremity bypassDual antiplatelet therapySingle antiplatelet therapyAntithrombotic therapyCombination therapyAntiplatelet therapyMedian odds ratioExtremity bypassDistal targetsHierarchical multivariable logistic regressionCenter-level variabilityCommon combination therapyPatient-level factorsPercutaneous coronary interventionPeripheral vascular interventionsMultivariable logistic regressionMultivariable regression modelsAntiplatelet monotherapyBypass targetAntithrombotic regimensPostoperative bleedingTriple therapyCoronary interventionAntithrombotic strategiesEscalation of Antithrombotic Therapy in Patients With Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization
Kim T, DeWan A, Murray M, Wang H, Mani A, Mena-Hurtado C, Guzman R, Chaar C. Escalation of Antithrombotic Therapy in Patients With Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization. Journal Of Vascular Surgery 2022, 75: e281. DOI: 10.1016/j.jvs.2022.03.640.Peer-Reviewed Original ResearchAntithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation
Freeman JV, Higgins AY, Wang Y, Du C, Friedman DJ, Daimee UA, Minges KE, Pereira L, Goldsweig AM, Price MJ, Reddy VY, Gibson D, Doshi SK, Varosy PD, Masoudi FA, Curtis JP. Antithrombotic Therapy After Left Atrial Appendage Occlusion in Patients With Atrial Fibrillation. Journal Of The American College Of Cardiology 2022, 79: 1785-1798. PMID: 35512858, PMCID: PMC9097170, DOI: 10.1016/j.jacc.2022.02.047.Peer-Reviewed Original ResearchConceptsLeft atrial appendage occlusionAdverse eventsPivotal trialsWatchman deviceTreatment protocolAntithrombotic strategiesAppendage occlusionLower riskFrailty regressionPercutaneous left atrial appendage occlusionNational Cardiovascular Data RegistryContemporary U.S. practiceDual antiplatelet therapyAtrial appendage occlusionConcomitant aspirinPostprocedure careAdjusted riskAntiplatelet therapyAntithrombotic medicationAntithrombotic therapyAtrial fibrillationAdverse outcomesTrial protocolAntithrombotic agentsMedication strategiesImpact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial
Welsh R, Dehghani P, Lopes R, Wojdyla D, Aronson R, Granger C, Windecker S, Vora A, Vinereanu D, Halvorsen S, Parkhomenko A, Mehran R, Alexander J, Goodman S. Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. Open Heart 2022, 9: e001892. PMID: 35172988, PMCID: PMC8852719, DOI: 10.1136/openhrt-2021-001892.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAspirinAtrial FibrillationFactor Xa InhibitorsFemaleHemorrhageHumansIschemiaMaleMedication Therapy ManagementMiddle AgedOutcome and Process Assessment, Health CarePercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPreoperative PeriodPyrazolesPyridonesVitamin KConceptsOral anticoagulant useVitamin K antagonistsClinically relevant non-major bleedingAcute coronary syndromePercutaneous coronary interventionNon-major bleedingOral anticoagulantsAtrial fibrillationAUGUSTUS trialOral anticoagulation statusElective percutaneous coronary interventionHAS-BLED scoreRisk of myocardial infarctionSecondary analysisHAS-BLEDK antagonistsOpen-labelHigher CHAPrimary endpointAntithrombotic therapyAnticoagulant useClinical outcomesCoronary syndromeIschaemic eventsRandomised treatment
2021
Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy
Zakko A, Zakko L, Grimshaw AA, Laine L. Antiplatelet Monotherapy Is Associated with an Increased Risk of Bleeding After Endoscopic Sphincterotomy. Digestive Diseases And Sciences 2021, 67: 4161-4169. PMID: 34796411, DOI: 10.1007/s10620-021-07302-w.Peer-Reviewed Original ResearchConceptsEndoscopic retrograde cholangiopancreatographyPost-sphincterotomy bleedingAntiplatelet monotherapyInclusion criteriaRisk of bleedingROBINS-I toolNewcastle-Ottawa ScaleHigh-quality studiesRandom-effects modelBackgroundClinical guidelinesAntithrombotic therapyAdult patientsCohort studyEndoscopic sphincterotomyPrimary outcomeAntiplatelet agentsOvid EmbaseRetrograde cholangiopancreatographyCochrane LibraryOvid MEDLINEMonotherapyMethodological qualityBleedingUnique citationsPatientsAntithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure
Lusk J, Xu H, Peterson E, Bhatt D, Fonarow G, Smith E, Matsouaka R, Schwamm L, Xian Y. Antithrombotic Therapy for Stroke Prevention in Patients With Ischemic Stroke With Aspirin Treatment Failure. Stroke 2021, 52: e777-e781. PMID: 34702067, PMCID: PMC8608737, DOI: 10.1161/strokeaha.121.034622.Peer-Reviewed Original ResearchConceptsAspirin treatment failureDual antiplatelet therapyIschemic strokeAspirin monotherapyClopidogrel monotherapyAntiplatelet therapyAntithrombotic therapyTreatment failureAntithrombotic treatment patternsAspirin/dipyridamoleGuidelines-Stroke registryIschemic stroke survivorsAcute ischemic strokeHalf of patientsAmerican Heart AssociationComplex clinical scenariosNonvitamin KOral anticoagulantsStroke preventionStroke RegistryOlder patientsPreventive therapyTreatment patternsHeart AssociationStroke survivorsPredictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study.
He L, Qin Y, Xu Y, Hu S, Wang Y, Zeng M, Feng X, Liu Q, Syed I, Demuyakor A, Zhao C, Chen X, Li Z, Meng W, Xu M, Liu H, Ma L, Dai J, Xing L, Yu H, Hou J, Jia H, Mintz G, Yu B. Predictors of non-stenting strategy for acute coronary syndrome caused by plaque erosion: four-year outcomes of the EROSION study. EuroIntervention 2021, 17: 497-505. PMID: 33164894, PMCID: PMC9724919, DOI: 10.4244/eij-d-20-00299.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeNon-TLR groupLong-term prognosisOptical coherence tomographyFollow-upAntithrombotic therapyCoronary syndromePredictor of long-term prognosisResponse to antithrombotic therapyTreated with antithrombotic therapyPlaque erosionLong-term follow-upTarget lesion revascularisationMedian durationPrimary endpointAntithrombotic strategiesOne-month follow-upThrombus reductionGastrointestinal bleedingAngiographic resultsCoherence tomographyStent implantationDiameter stenosisClinic visitsPatientsIntermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial
Bikdeli B, Talasaz AH, Rashidi F, Bakhshandeh H, Rafiee F, Rezaeifar P, Baghizadeh E, Matin S, Jamalkhani S, Tahamtan O, Sharif-Kashani B, Beigmohammadi MT, Farrokhpour M, Sezavar SH, Payandemehr P, Dabbagh A, Moghadam KG, Khalili H, Yadollahzadeh M, Riahi T, Abedini A, Lookzadeh S, Rahmani H, Zoghi E, Mohammadi K, Sadeghipour P, Abri H, Tabrizi S, Mousavian SM, Shahmirzaei S, Amin A, Mohebbi B, Parhizgar SE, Aliannejad R, Eslami V, Kashefizadeh A, Dobesh PP, Kakavand H, Hosseini SH, Shafaghi S, Ghazi SF, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Maleki M, Sadeghian S, Piazza G, Kirtane AJ, Van Tassell BW, Stone GW, Lip GYH, Krumholz H, Goldhaber SZ, Sadeghipour P. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial. Thrombosis And Haemostasis 2021, 122: 131-141. PMID: 33865239, DOI: 10.1055/a-1485-2372.Peer-Reviewed Original ResearchConceptsStandard-dose prophylactic anticoagulationExtracorporeal membrane oxygenationProphylactic anticoagulationIntermediate doseEfficacy outcomesArterial thrombosisCOVID-19Hospital discharge statusMain safety outcomeProphylactic antithrombotic therapyComposite of deathCritically ill patientsPrimary efficacy outcomeStandard-dose groupIntermediate-dose groupIntensive care unitCoronavirus disease 2019Cause deathMajor bleedingModified intentionOpen labelAntithrombotic therapyExtrapulmonary manifestationsHospital dischargeThrombotic complications
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply